PDF, Patent Landscape Report on Atazanavir - WIPO

ContentsSECTION 1: THE TWO OBJECTIVES OF THE PROJECT ................................................. 4STUDYING DEVELOPMENT OF DRUGS THROUGH PATENTS ................................... 4BEST PRACTICES FOR COLLECTING AND ANALYZING PATENTS............................ 4ORGANIZATION OF THE REPORT................................................................................. 4SECTION 2: BUILDING A PATENT COLLECTION COVERING ATAZANAVIR .................. 6CHEMICAL NAMING ........................................................................................................ 7SUPPLEMENTAL PROTECTION CERTIFICATES .......................................................... 7CLINICAL NAMING..........................................................................................................10MANUFACTURER NAMING............................................................................................10GENERIC NAMING .........................................................................................................10BRAND NAMING .............................................................................................................10SECTION 3: PREPARING THE CLINICAL COLLECTION..................................................11STAGE ONE STRATEGY................................................................................................11STAGE TWO CLINICAL SEARCH ..................................................................................13CLINICAL COLLECTION .................................................................................................14CLINICAL COLLECTION .................................................................................................15SECTION 4: PREPARING THE CHEMICAL COLLECTION ...............................................16MULTI-FACETED APPROACH .......................................................................................16THE FOUNDER PATENT AND ITS DOWNSTREAM CITATIONS..................................17CHEMICAL COLLECTION...............................................................................................17CHEMICAL COLLECTION...............................................................................................18CHEMICAL COLLECTION...............................................................................................19SUMMARY OF COLLECTION ASSEMBLY.....................................................................20SECTION 5: GENERAL OVERVIEW OF THE COLLECTION ............................................21EARLIEST PRIORITY COUNTRY ...................................................................................21EARLIEST PRIORITY COUNTRY ...................................................................................22FAMILY MEMBER COUNTRIES .....................................................................................22FAMILY MEMBER COUNTRIES .....................................................................................23SECTION 6: EXAMINING ASPECTS OF DRUG DEVELOPMENT ....................................23SECTION 6: EXAMINING ASPECTS OF DRUG DEVELOPMENT ....................................24THE DEVELOPER’S OWN TIMELINE.............................................................................272